New Harris Poll: Cybersecurity Fears May Stall COVID-19 Digital Vaccine Card Adoption in the United Kingdom, Identity Theft and Fake Cards Top List of Concerns
29.7.2021 18:02:00 EEST | Business Wire | Press release
Anomali, the leader in intelligence-driven cybersecurity solutions, today announced availability of its latest survey conducted by The Harris Poll. The study, which gathered responses from more than 1,000 adults aged 18 and over in the United Kingdom, reveals that more than three-quarters of British adults have cybersecurity fears around the use of COVID-19 digital vaccination cards. Additional findings showed which entities respondents believe are responsible for protecting them against cyberattacks and who they believe the most likely culprits will be.
A majority of respondents predict that a disruptive cyberattack will follow digital vaccine card adoption, findings also reveal confidence levels when it comes to how prepared the nation is to mount a defense. Among key findings:
- 76% have cybersecurity concerns related to COVID-19 digital vaccination cards. Identity theft topped the list at 51%, with fake vaccine cards that could be used to hack smartphones (44%) and data breaches (45%) close behind.
- 89% have smartphones capable of supporting COVID-19 digital vaccination cards. In contrast, a survey conducted a little over a year ago by Anomali and Censuswide showed that half of respondents knew someone that did not possess smartphones necessary to use healthcare technologies such as contract tracing apps.
- 54% say they are “very likely” to use COVID-19 digital vaccination cards if they become a requirement for certain activities, such as traveling, attending sports venues, school attendance, entering a store or government building, etc. However, doubt remains, as 26% said they are “somewhat” likely. A full 21% rejected the idea of using digital vaccine cards, stating they are not likely to use them at all.
- 64% expect that COVID-19 digital vaccination cards will lead to a cyberattack causing “moderate to major” disruption to business, government, and consumers. 27% said that disruption would only be “slight” while 9% do not expect any related disruptions.
- When asked to identify what type of adversary is most likely to carry out a cyberattack related to COVID-19 digital vaccination cards, organized cybercriminal gangs were most frequently cited (42%).
- 64% “somewhat to strongly” agree that government and private business is prepared to defend consumers against a related cyberattack. 74% said the government was most responsible for providing defense.
- Although COVID-19 passport standards haven’t been established, when asked to pick from a list of organizations that will most likely be responsible for creating and managing standards, the government was most frequently cited (55%), the World Health Organization (WHO) came in second (44%).
“Over the course of the pandemic, our intelligence analysts detected thousands of cyberattacks that were taking advantage of people’s desire to consume information online about how COVID-19 was impacting their lives and world. We’ve detected adversaries doing everything from using fake contact tracing apps to hijack smart phones and steal credentials to launching mass phishing campaigns to infect networks with things like ransomware,” said Hugh Njemanze, President, Anomali. “The easing of restrictions, rise in cyberattacks, and consumers’ willingness to use their smartphones to break free from restrictive lockdowns are at a nexus. Organizations responsible for keeping consumers and businesses safe online need to know who the adversaries are, where the attacks are coming from, and how to detect them before they develop into catastrophes.”
- Download the ebook: COVID-19: The Global Health Pandemic and Cybersecurity Challenges
- Read the blog: The COVID-19 Pandemic Changed Everything, Can You Detect the New Normal?
- View the infographic: COVID-19 DIGITAL VACCINE EFFORTS MAY STALL AMID FEARS
Methodology
This survey was conducted online by The Harris Poll on behalf of Anomali from June 30 – July 7, 2021 among 1,007 U.K. adults all ages 18 and older. Raw data were weighted by the following demographic variables where necessary to reflect the general adult population as follows: age, gender, education, region, race, HH size, and marital status. Propensity score weighting was also used to adjust for respondents’ propensity to be online. This online survey is not based on a probability sample and therefore no estimate of theoretical sampling error can be calculated.
Twitter: https://twitter.com/Anomali
LinkedIn: https://www.linkedin.com/company/anomali/
Blog: https://www.anomali.com/blog
About The Harris Poll
The Harris Poll is one of the longest-running surveys in the U.S., tracking public opinion, motivations and social sentiment since 1963. It is now part of Harris Insights & Analytics, a global consulting and market research firm that strives to reveal the authentic values of modern society to inspire leaders to create a better tomorrow. We work with clients in three primary areas; building twenty-first century corporate reputation, crafting brand strategy and performance tracking, and earning organic media through public relations research. Our mission is to provide insights and advisory to help leaders make the best decisions possible.
About Anomali
Anomali is the leader in global intelligence-driven cybersecurity. Our customers rely on us to see and detect threats, stop breaches, stop attackers, elevate resiliency, and improve the productivity of their security operations. Our solutions serve customers around the world in every major industry vertical, including many of the Global 1000. We are a SaaS company that offers native cloud, multi-cloud, on-premises, and hybrid technologies. As an early threat intelligence innovator, Anomali was founded in 2013 and is backed by leading venture firms including Google Ventures, IVP, General Catalyst, and several others. Learn more at www.anomali.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005800/en/
Contact information
Joe Franscella
news@anomali.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
